ArticleFrontiers in medicine2025
CT-guided percutaneous aspiration and bleomycin sclerotherapy for symptomatic hepatic cysts: technique and three-year outcomes.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to evaluate the long-term efficacy and safety of CT-guided percutaneous aspiration and bleomycin sclerotherapy for symptomatic hepatic cysts at a minimum follow-up of 3 years. Materials and methods: Medical records of patients who underwent CT-guided percutaneous aspiration and bleomycin sclerotherapy for large (>5 cm) symptomatic simple hepatic cysts and polycystic liver disease were reviewed retrospectively. The choice of percutaneous needle or catheter aspiration was based on the estimated cyst volume. The administered dose of bleomycin was calculated at 5 mg per 100 mL of cyst fluid, with a maximum dose not exceeding 0.6-0.8 mg/kg of body weight per patient. Clinical outcomes, including symptom relief evaluated by the Chronic Liver Disease Questionnaire and the technical response defined by the cyst volume reduction rate, were assessed at 6-, 12-, 24-, and 36-month follow-ups post-sclerotherapy. Results: A total of 96 cysts in 88 patients (mean age 61.8 ± 18.2 years; 56.8% female) were treated with single-session percutaneous aspiration and bleomycin sclerotherapy. Of these, 81 patients had symptomatic simple hepatic cysts, while 7 had polycystic liver disease. The total bleomycin dose administered ranged from 10 mg to 50 mg per patient, with a median dose of 41.0 mg. All patients reported significant symptom relief, with 81 patients (92.0%) experiencing complete symptom resolution and 7 patients (8.0%) with polycystic liver disease showing improvement from 12 months to 36 months post-procedure. The overall response rates at 6, 12, 24, and 36 months were 96.9% (93 of 96), 100% (96 of 96), 100% (96 of 96), and 100% (96 of 96), respectively. No major complications or bleomycin-related toxicities were observed during or after the procedure. Conclusion: CT-guided single-session percutaneous aspiration and bleomycin sclerotherapy is an effective and safe treatment for symptomatic simple hepatic cysts and polycystic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.